Familial Mediterranean fever (FMF) and renal AA amyloidosis - Phenotype-genotype correlation, treatment and prognosis

被引:0
|
作者
Ben-Chetrit, E [1 ]
机构
[1] Hadassah Univ Hosp, Dept Med, FMF Clin, Jerusalem, Israel
关键词
amyloidosis; FAT; colchicine; renal failure;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Familial Mediterranean fever (FMF) is an autosomal recessive disease, which primarily affects the population surrounding the Mediterranean basin. It is characterized by recurrent attacks of fever and peritonitis, pleuritis, arthritis or erysipelas-like erythema. Amyloidosis, causing renal failure, is one of the most severe complications of the disease. The gene associated with FMF (MEFV) has been recently isolated. Phenotype-genotype correlation studies revealed that amyloidosis was more common in FMF patients originating from North-Africa who were homozygous for the M694V mutation. Such a correlation was not found in Turkish patients. The risk of amyloidosis is increased in male FMF patients and in patients bearing polymorphism a/a in the SARI gene. Colchicine is the chosen drug for the treatment of FMF and can prevent amyloidosis.
引用
收藏
页码:431 / 434
页数:4
相关论文
共 50 条
  • [31] Tocilizumab Is Effective in the Treatment of AA Amyloidosis Secondary to Familial Mediterranean Fever
    Ozdogan, Huri
    Ugurlu, Serdal
    Hacioglu, Aysa
    Adibnia, Yasaman
    Hamuryudan, Vedat
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [32] Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever
    Yilmaz, Sedat
    Cinar, Muhammet
    Simsek, Ismail
    Erdem, Hakan
    Pay, Salih
    RHEUMATOLOGY, 2015, 54 (03) : 564 - 565
  • [33] SPECTRUM OF RENAL INVOLVEMENT IN FAMILIAL MEDITERRANEAN FEVER (FMF)
    SAID, R
    HAMZEH, Y
    TARAWNEH, M
    AIKHATEEB, M
    KIDNEY INTERNATIONAL, 1989, 35 (01) : 212 - 212
  • [34] Phenotype–genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloidosis
    M Shohat
    N Magal
    T Shohat
    X Chen
    T Dagan
    A Mimouni
    Y Danon
    R Lotan
    G Ogur
    A Sirin
    M Schlezinger
    GJ Halpern
    A Schwabe
    D Kastner
    JI Rotter
    N Fischel-Ghodsian
    European Journal of Human Genetics, 1999, 7 : 287 - 292
  • [35] Colchicine in the treatment of renal amyloidosis secondary to familial Mediterranean fever
    Sarkissian, A
    Papazian, M
    Sanamyan, A
    Leumann, E
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (07) : 1098 - 1098
  • [36] Genotype-phenotype correlation in patients with Familial mediterranian fever (FMF) in east Anatolia of Turkey
    Albayrak, F
    Selcuk, NY
    Odabas, AR
    Cetinkaya, R
    Pirim, I
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V281 - V281
  • [37] MEFV mutations and phenotype-genotype correlations in North African Jews and Armenians with familial Mediterranean fever
    Cattan, D
    Dervichian, M
    Thomas, M
    Dode, C
    Touitou, I
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2001, 3 (11): : 803 - 804
  • [38] Tocilizumab (TCZ) in the Treatment of AA Amyloidosis in Patients with Familial Mediterranean Fever.
    Ozdogan, Huri
    Ugurlu, Serdal
    Hacioglu, Aysa
    Adibnia, Yasaman
    Hamuryudan, Vedat
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S540 - S541
  • [39] Infliximab treatment of familial Mediterranean fever and its effect on secondary AA amyloidosis
    Metyas, S
    Arkfeld, DG
    Forrester, DM
    Ehresmann, GR
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2004, 10 (03) : 134 - 137
  • [40] Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever
    Serdal Ugurlu
    Aysa Hacioglu
    Yasaman Adibnia
    Vedat Hamuryudan
    Huri Ozdogan
    Orphanet Journal of Rare Diseases, 12